Sandra Feijóo-Bandín

Dr. Sandra Feijóo-Bandín

Health Research Institute of Santiago de Compostela, Santiago de Compostela, Galicia, Spain
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
AAAlana Aragón-Herrera
Alana Aragón-Herrera
SFSandra Feijóo-Bandín
Sandra Feijóo-Bandín
MSManuel Otero Santiago
Manuel Otero Santiago
LBLuis Barral
Luis Barral
Manuel Campos-ToimilManuel Campos-Toimil
Manuel Campos-Toimil
FLFrancisca Lago
Francisca Lago

Verified
Journal Article
Open access
PDF file
SFSandra Feijóo-Bandín
Sandra Feijóo-Bandín
AAAlana Aragón-Herrera
Alana Aragón-Herrera
SFSandra Moraña Fernández
Sandra Moraña Fernández
LALaura Anido-Varela
Laura Anido-Varela
ETEstefanía Tarazón
Estefanía Tarazón
FLFrancisca Lago
Francisca Lago
It is well established that adipose tissue, apart from its energy storage function, acts as an endocrine organ that produces and secretes a number of bioactive substances, including hormones commonly known as adipokines. Obesity is a major risk factor for the development of cardiovascular diseases, mainly due to a low grade of inflammation and the excessive fat accumulation produced in this state. The adipose tissue dysfunction in obesity leads to an aberrant release of adipokines, some of them with direct cardiovascular and inflammatory regulatory functions. Inflammation is a common link between obesity and cardiovascular diseases, so this review will summarise the role of the main adipokines implicated in the regulation of the inflammatory processes occurring under the scenario of cardiovascular diseases.

Verified
Journal Article
Open access
PDF file
SFSandra Feijóo-Bandín
Sandra Feijóo-Bandín
AAAlana Aragón-Herrera
Alana Aragón-Herrera
MOManuel Otero-Santiago
Manuel Otero-Santiago
LALaura Anido-Varela
Laura Anido-Varela
SMSandra Moraña-Fernández
Sandra Moraña-Fernández
FLFrancisca Lago
Francisca Lago
Sodium-glucose co-transporter 2 inhibitors, also known as gliflozins, were developed as a novel class of anti-diabetic agents that promote glycosuria through the prevention of glucose reabsorption in the proximal tubule by sodium-glucose co-transporter 2. Beyond the regulation of glucose homeostasis, they resulted as being effective in different clinical trials in patients with heart failure, showing a strong cardio-renal protective effect in diabetic, but also in non-diabetic patients, which highlights the possible existence of other mechanisms through which gliflozins could be exerting their action. So far, different gliflozins have been approved for their therapeutic use in T2DM, heart failure, and diabetic kidney disease in different countries, all of them being diseases that have in common a deregulation of the inflammatory process associated with the pathology, which perpetuates and worsens the disease. This inflammatory deregulation has been observed in many other diseases, which led the scientific community to have a growing interest in the understanding of the biological processes that lead to or control inflammation deregulation in order to be able to identify potential therapeutic targets that could revert this situation and contribute to the amelioration of the disease. In this line, recent studies showed that gliflozins also act as an anti-inflammatory drug, and have been proposed as a useful strategy to treat other diseases linked to inflammation in addition to cardio-renal diseases, such as diabetes, obesity, atherosclerosis, or non-alcoholic fatty liver disease. In this work, we will review recent studies regarding the role of the main sodium-glucose co-transporter 2 inhibitors in the control of inflammation.

18 August 2017 in Frontiers in Physiology
Verified
Journal Article
Open access
SFSandra Feijóo-Bandín
Sandra Feijóo-Bandín
AAAlana Aragón-Herrera
Alana Aragón-Herrera
DRDiego Rodríguez-Penas
Diego Rodríguez-Penas
MPManuel Portolés
Manuel Portolés
EREsther Roselló-Lletí
Esther Roselló-Lletí
FLFrancisca Lago
Francisca Lago
Despite the great effort of the medical community during the last decades, cardiovascular diseases remain the leading cause of death worldwide, increasing their prevalence every year mainly due to our new way of life. In the last years, the study of new hormones implicated in the regulation of energy metabolism and inflammation, especially adipokines, has raised a great interest among the scientific community regarding their implications in the development of cardiometabolic diseases. In this review, we will summarize the main actions of relaxin, a pleiotropic hormone that was previously probed to improve acute heart failure and that participates in both metabolism and inflammation regulation at cardiovascular level, and will discuss its potential as future therapeutic target to prevent/reduce cardiovascular diseases.

Verified
Journal Article
Open access
PDF file
AAAlana Aragón-Herrera
Alana Aragón-Herrera
SFSandra Feijóo-Bandín
Sandra Feijóo-Bandín
LALaura Anido-Varela
Laura Anido-Varela
SMSandra Moraña-Fernández
Sandra Moraña-Fernández
ELEsther Roselló Lletí
Esther Roselló Lletí
FLFrancisca Lago
Francisca Lago
The pleiotropic hormone relaxin-2 plays a pivotal role in the physiology and pathology of the cardiovascular system. Relaxin-2 exerts relevant regulatory functions in cardiovascular tissues through the specific receptor relaxin family peptide receptor 1 (RXFP1) in the regulation of cardiac metabolism; the induction of vasodilatation; the reversion of fibrosis and hypertrophy; the reduction of inflammation, oxidative stress, and apoptosis; and the stimulation of angiogenesis, with inotropic and chronotropic effects as well. Recent preclinical and clinical outcomes have encouraged the potential use of relaxin-2 (or its recombinant form, known as serelaxin) as a therapeutic strategy during cardiac injury and/or in patients suffering from different cardiovascular disarrangements, especially heart failure. Furthermore, relaxin-2 has been proposed as a promising biomarker of cardiovascular health and disease. In this review, we emphasize the relevance of the endogenous hormone relaxin-2 as a useful diagnostic biomarker in different backgrounds of cardiovascular pathology, such as heart failure, atrial fibrillation, myocardial infarction, ischemic heart disease, aortic valve disease, hypertension, and atherosclerosis, which could be relevant in daily clinical practice and could contribute to comprehending the specific role of relaxin-2 in cardiovascular diseases.

14 March 2023 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
AAAlana Aragón-Herrera
Alana Aragón-Herrera
SMSandra Moraña-Fernández
Sandra Moraña-Fernández
MOManuel Otero-Santiago
Manuel Otero-Santiago
LALaura Anido-Varela
Laura Anido-Varela
MCManuel Campos-Toimil
Manuel Campos-Toimil
FLFrancisca Lago
Francisca Lago
The pharmacological inhibition of sodium-glucose cotransporter 2 (SGLT2) has emerged as a treatment for patients with type 2 diabetes mellitus (T2DM), cardiovascular disease and/or other metabolic disturbances, although some of the mechanisms implicated in their beneficial effects are unknown. The SGLT2 inhibitor (SGLT2i) empagliflozin has been suggested as a regulator of adiposity, energy metabolism, and systemic inflammation in adipose tissue. The aim of our study was to evaluate the impact of a 6-week-empagliflozin treatment on the lipidome of visceral (VAT) and subcutaneous adipose tissue (SAT) from diabetic obese Zucker Diabetic Fatty (ZDF) rats using an untargeted metabolomics approach. We found that empagliflozin increases the content of diglycerides and oxidized fatty acids (FA) in VAT, while in SAT, it decreases the levels of several lysophospholipids and increases 2 phosphatidylcholines. Empagliflozin also reduces the expression of the cytokines interleukin-1 beta (IL-1β), IL-6, tumor necrosis factor-alpha (TNFα), monocyte-chemotactic protein-1 (MCP-1) and IL-10, and of Cd86 and Cd163 M1 and M2 macrophage markers in VAT, with no changes in SAT, except for a decrease in IL-1β. Empagliflozin treatment also shows an effect on lipolysis increasing the expression of hormone-sensitive lipase (HSL) in SAT and VAT and of adipose triglyceride lipase (ATGL) in VAT, together with a decrease in the adipose content of the FA transporter cluster of differentiation 36 (CD36). In conclusion, our data highlighted differences in the VAT and SAT lipidomes, inflammatory profiles and lipolytic function, which suggest a distinct metabolism of these two white adipose tissue depots after the empagliflozin treatment.